Medicare covers deep brain stimulation (DBS) for eligible people diagnosed with essential tremors or idiopathic Parkinson’s disease to help reduce tremors and improve daily activities. To qualify for ...

If deep brain stimulation (DBS) can help people with Parkinson’s disease walk and speak again, could it help people with Alzheimer’s disease, too? It’s a natural question, and one that researchers are ...

Deep brain stimulation enhances memory, may ease Alzheimer's symptoms. Feb. 8, 2012— -- A new study suggests that driving electricity deep into the brain can boost memory, shedding light on a ...

There is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain stimulator that could benefit patients with the motor condition. On Feb 24, ...

Combining virtual reality and non-invasive deep-brain electrical stimulation, researchers have improved healthy individuals’ spatial memory – the kind that helps you remember where you left the car ...

Being able to noninvasively stimulate the deep brain without stimulating shallow regions is a key goal of non-invasive ...

Swedish neurotech startup Flow Neuroscience has secured FDA approval for the first brain stimulation device for home use in ...

Deep brain stimulation can significantly reduce depressive symptoms in some individuals. Knowing what to expect before and after the procedure may help you determine if it’s right for you. Deep brain ...

Two patients with spinal injuries have seen improvements in their ability to walk again, thanks to deep brain stimulation (DBS). Intriguingly, the therapy targets a region of the brain that normally ...

Personalized, adaptive deep brain stimulation (DBS) can enhance the control of motor symptoms of Parkinson's disease (PD) compared with standard DBS, new research suggests. In a blinded randomized ...

Deep brain stimulation—implants in the brain that act as a kind of "pacemaker"—has led to clinical improvements in half of the participants with treatment-resistant severe depression in an open-label ...